TrialLancet (London, England)2019

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.

Andrew R Clamp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.